Skip to content

Inspection Record

Guangdong Bangze Medicine Co., Ltd. — FDA Warning Letter Findings

US FDAPublished 2026-11-03 3 findingsLaboratory and QC controlsMaterial and supplier controlQuality unit oversight

View the regulator's official source The source document is always the basis for judgement.

Findings

1Laboratory and QC controls

Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release. Your firm also failed to conduct appropriate laboratory testing, as necessary, for each batch of drug product required to be free of objectionable microorganisms (21 CFR 211.165(a) and 211.165(b)). Based on the records and information you provided, you did not demonstrate that you adequately test your OTC finished drug products prior to release for distribution to the United States. Specifically, the certificate of analyses (COA) that you provided did not include identity, assay, or impurity test results. In addition, the COAs provided also reveal that you lacked appropriate testing for objectionable microorganisms for each batch. Testing is an essential part of CGMP to ensure that the drug products you manufacture conform to all pre-determined quality attributes appropriate for their intended use. Drug products must be tested for identity and strength of the active ingredient prior to release and distribution. Without adequate testing, you do not have scientific evidence to assure that your drug products conform to appropriate specifications before release.

2Material and supplier control

Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)(1) and 211.84(d)(2)). Your firm manufactures OTC drug products including (b)(4) . Based on the records and information you provided, you did not demonstrate that you adequately tested the identity, purity, or strength of components used in the manufacture of your drug products. You also relied on your suppliers' certificates of analysis (COA) for (b)(4) without demonstrating the reliability of your suppliers' test analyses at appropriate intervals. (b)(4) Your incoming inspection records for your (b)(4) active ingredient failed to include appropriate compendial identity testing, assay, or impurity testing. You manufacture drugs that contain (b)(4) . The use of (b)(4) contaminated with (b)(4) has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document (b)(4). (b)(4) Your incoming inspection records for your (b)(4) component similarly failed to include compendial identity testing and lacked appropriate (b)(4) limit testing. Identity testing for (b)(4) and certain other high-risk drug components includes a limit test in the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for levels of (b)(4) . The use of ingredients contaminated with (b)(4) has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document (b)(4) (b)(4) Based on the records you provided, you did not perform appropriate (b)(4) testing, including (b)(4) testing, on the (b)(4) used to manufacture your drug products. Your (b)(4) specifications reference the Chinese Pharmacopeia rather than USP for (b)(4) . Without adequate (b)(4) testing, you do not have scientific evidence that the (b)(4) used as a component in your drug product manufacturing conforms to appropriate specifications. Component testing is fundamental to quality. Without adequate testing, you do not have scientific evidence that your components conform to appropriate specifications prior to use in the manufacture of your drug products. As a manufacturer, you have a responsibility to sample, test, and examine drug components before use in production to assure adequate quality.

3Quality unit oversight

Your firm’s quality unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22). The records and information you provided demonstrate that your quality unit (QU) did not effectively exercise its responsibilities to oversee the quality of your drug manufacturing operations. For example, your QU failed to ensure: The establishment of an adequate, ongoing stability program (21 CFR 211.166(a)). Adequate procedures ensuring appropriate production and process controls, including appropriate qualification of the (b)(4) system (21 CFR 211.100(a)). Your firm’s quality systems are inadequate. For help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211, see FDA’s guidance documents Quality Systems Approach to Pharmaceutical CGMP Regulations at https://www.fda.gov/media/71023/download. CGMP Consultant Recommended Based upon the nature of the violations we identified in your response, you should engage a consultant qualified as set forth in 21 CFR 211.34, to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.

Sections cited in this document

A record as of the US FDA document published on 2026-11-03. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Guangdong Bangze Medicine Co., Ltd. company profile — full historyAll US FDA findings US FDA documents, 2026 Go to Findings search
Linked from (backlinks)
Briefs that featured this document
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.